About
SetPoint Medical is a commercial-stage medical technology company founded in 2007. The company focuses on developing innovative therapies for chronic autoimmune diseases by integrating scientific discovery, precision engineering, and business expertise. Its flagship product, the FDA-approved SetPoint System, is a neuroimmune modulation device designed for adults with moderate-to-severe rheumatoid arthritis who do not respond adequately to or cannot tolerate existing advanced therapies. The SetPoint System delivers targeted electrical stimulation to the vagus nerve, activating the body’s anti-inflammatory pathways. This approach reduces systemic inflammation and restores immunologic balance without broadly suppressing the immune system. Clinical evidence indicates that a single one-minute stimulation can significantly suppress inflammatory cytokines for over 24 hours. SetPoint Medical plans to expand the availability of the SetPoint System across the U.S. following its initial launch in targeted cities in 2025, with ongoing studies for other chronic autoimmune conditions. Led by CEO Murthy V. Simhambhatla, Ph.D., SetPoint Medical collaborates with healthcare providers and payers to enhance access to its therapy, aiming to improve patient outcomes and quality of life.
Technologies
Keywords
Company Information
-
Employees 87
-
Founded 2007
-
Annual Revenue $22600000
-
Total Funding $444699986
Location
25101 Rye Canyon Loop, Santa Clarita, California, United States, 91355
